Evidence method
Level · gp.fundamentals.capex_revenue_ratio
10232.43% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
FDMT · Dec 31, 2024
4D Molecular Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-25-030056General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-363743.24% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
-99.82% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-507678.38% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
70583.78% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History7 statesHistory building
Period transition
What moved in the state?
- Previous
- 59266.67%
- Current
- 10232.43%
- Delta
- -49034.23%
- Previous
- -979700.00%
- Current
- -363743.24%
- Delta
- 615956.76%
- Previous
- -1704400.00%
- Current
- -507678.38%
- Delta
- 1196721.62%
- Previous
- 216333.33%
- Current
- 70583.78%
- Delta
- -145749.55%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.